Microbiotica

Microbiotica, founded in December 2016 and based in Cambridge, UK, is a developer of human microbiome therapies focused on discovering and developing live bacterial therapeutics and biomarkers. The company is building a differentiated product pipeline based on high-quality clinical datasets and unique bacterial signatures driven by biology, identified through its proprietary platform. Its current therapeutic focus areas are immuno-oncology and IBD, where it has established key clinical and academic partnerships. The company has a strategic collaboration with Genentech, a member of the Roche Group, in the inflammatory bowel disease (IBD) space, as well as with the University of Adelaide to develop a defined product for ulcerative colitis.